Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.43 |
| ▸ | FLT1 | P17948 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5184813 | 0.90 | NPSR1 (0.49) | KDRFLT1RAB9ANPC1ALDH1A1 | |
| SCHEMBL4950199 | 0.86 | KDR (0.39) | KDRFLT1RAB9AALDH1A1NPSR1 | |
| SCHEMBL4952020 | 0.83 | CNR1 (0.41) | KDRHDAC4TRPV1 | |
| SCHEMBL5184705 | 0.82 | NPC1 (0.51) | RAB9ANPC1ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL5185017 | 0.80 | RAB9A (0.46) | KDRRAB9ANPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5183675 | 0.79 | NPSR1 (0.51) | KDRFLT1RAB9ANPC1ALDH1A1 | |
| SCHEMBL5185052 | 0.78 | KDM4E (0.48) | RAB9ANPC1ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL5184088 | 0.78 | TRPV1 (0.45) | RAB9ANPC1ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL4949892 | 0.77 | CNR1 (0.49) | KDRRAB9ANPC1SMN1; SMN2NPSR1 | |
| SCHEMBL5183511 | 0.77 | KDM4E (0.47) | RAB9ANPC1ALDH1A1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | REMPEX PHARMACEUTICALS, INC. | 2008-03-27 | — | — | US | disclosed |
| EP-1758920-A1 | BACTERIAL EFFLUX PUMP INHIBITORS AND METHODS OF TREATING BACTERIAL INFECTIONS | MPEX PHARMACEUTICALS, INC. (US) | 2007-03-07 | — | — | EP | disclosed |
| US-20060003944-A1 | Bacterial efflux pump inhibitors and methods of treating bacterial infections | REMPEX PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
| WO-2005113579-A1 | BACTERIAL EFFLUX PUMP INHIBITORS AND METHODS OF TREATING BACTERIAL INFECTIONS | MPEX PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | ABCB1, ABCB11, SLC47A2 | KDR 4532/4885FLT1 4753/4885RAB9A 534/4885 |
| US-20060003944-A1 | Bacterial efflux pump inhibitors and methods of treating bacterial infections | ABCB11, ABCB1, ABCC1 | KDR 4598/4885FLT1 4515/4885RAB9A 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.